To investigate the effect of hypoglycaemia on platelet and coagulation activation in people with type 2 diabetes.
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Conclusion: A single event of insulin-induced hypoglycaemia led to an increase in markers of platelet activation and coagulation in people with early stages of type 2 diabetes on metformin therapy. However, the activation occurred with a delay and was evident 24 hours and 7 days after the actual hypoglycaemic episode.
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| INTRODUCTION
While some studies have demonstrated cardiovascular benefits of intensive glucose control, 1 others were not able to replicate these effects [2] [3] [4] [5] or even showed increased mortality rates associated with intensive glucose control. 3 Hypoglycaemic events, which are an integral part of treatment regimens with sulphonylureas or insulin, were suggested to be one potential cause of the increase in mortality seen in the ACCORD trial 3 and several analyses have demonstrated an increase in cardiovascular and overall mortality associated in particular with severe hypoglycaemic events. [6] [7] [8] [9] [10] [11] A couple of pathophysiological theories have been put forward to explain the potential harmful atherothrombotic effects of hypoglycaemic events. 12 One was activation of the sympathetic nervous system, which induces the release of counterregulatory hormones (eg, catecholamines) as a response to the hypoglycaemic state, leading to haemodynamic changes with increased cardiac workload as well as derailments of potassium levels and provoking cardiac arrhythmia, QT interval prolongation and sudden cardiac death. [13] [14] [15] The second explanation frequently mentioned is the activation of platelets and the coagulation system by hypoglycaemic episodes, subsequently increasing the risk of atherothrombotic events. [16] [17] [18] [19] Studies investigating the proatherothrombotic effects of hypoglycaemia on platelet activity, however, were mainly performed in healthy individuals or in people with type 1 diabetes, and data on the population with type 2 diabetes remain scarce. 17, [20] [21] [22] In addition, these studies did not systematically evaluate the hypoglycaemic threshold at which potential platelet and coagulation activation may occur or how sustainable such an activation would be.
In the present study, we aimed to explore platelet activation as well as atherothrombotic and inflammation biomarkers in people at an early stage of type 2 diabetes on metformin monotherapy, without established cardiovascular disease and without platelet aggregation inhibitor therapy during a stepwise hypoglycaemic clamp experiment and a follow-up 7 days after the clamp event.
| MATERIALS AND METHODS

| Participants
The study participants were aged between 18 and 64 years (both inclusive) at screening/enrolment, were diagnosed with type 2 diabetes according to American Diabetes Association criteria, 23 were on either stable monotherapy with metformin for a period of 90 days prior to screening or diet only, had a body mass index (BMI) between 20.0 and 35.0 kg/m 2 (both inclusive) and a glycated haemoglobin (HbA1c) concentration between 43 and 64 mmol/moL (6.0%-8.0%; both inclusive). The main exclusion criteria were: use of any platelet-inhibiting therapy; treatment with β-blockers or other antiarrhythmic agents; impaired hypoglycaemia awareness; medical history of cardiac arrhythmia or uncontrolled hypertension; previously known established cardiovascular disease and/or past cardiovascular events, or past episodes of congestive heart failure syndrome (New York Heart Association grade II-IV); active smoking; clinically significant abnormal haematology, biochemistry, lipid levels, hormone levels or coagulation values at the screening visit; and use of neuroleptic drugs or intake of illicit substances. If a participant was treated with non-steroidal anti-inflammatory drugs (NSAIDs) or metamizole within 10 days prior to the clamp visits and/or their fasting plasma glucose was higher than 9.0 mmol/L on the day of the clamp investigations, the clamp visit was postponed for 10 to 15 days.
The Ethics Committee of the Medical University of Graz, Austria, approved the study (Ethics Committee number: EK30-012ex17/1) and all participants gave written consent prior to any study-related procedures. The study was conducted in accordance with the Declaration of Helsinki as well as the guidelines laid down by the International Conference on Harmonization for Good Clinical Practice (ICH GCP E6 guidelines). Participants were recruited using a local recruitment registry (Graz Diabetes Registry for Biomarker Research, GIRO). The study was registered at clinical trials.gov (https://clinicaltrials.gov/ct2/ show/NCT03460899│NCT03460899). 
| Study design
| Hyperinsulinaemic-euglycaemic clamp experiment
To rule out activation of platelets and coagulation by hyperinsulinaemia rather than insulin-induced hypoglycaemia, we perfomed a hyperinsulinaemic-euglycaemic clamp experiment. A variable intravenous infusion of glucose 20% or human rapid-acting insulin was initiated in order to obtain a plasma glucose target of 5.5 mmol/L ± 10%. After achieving this glucose target, a continuous insulin infusion (2.5 mU/kg/min) was applied for 120 minutes, together with a variable infusion of glucose 20% to maintain serum glucose concentrations at the prespecified level. Blood samples for measurement of plasma glucose concentrations were obtained at 5-minute intervals.
For measurements of platelet and coagulation activation, blood samples were collected at timepoints 0, 60, 90 and 120 minutes.
Having analysed the results we amended the protocol and performed another euglycaemic clamp experiment in people willing to participate again, and measured platelet and coagulation activation also 1 day and 7 days after the clamp experiment.
| Hyperinsulinaemic-hypoglycaemic clamp experiment
After initial stabilization of plasma glucose at 5.5 mmol/L using a variable insulin or glucose 20% infusion, a constant insulin infusion of 2.5 mU/kg/min was initiated. Variable glucose 20% infusion was applied to maintain the target plasma glucose level of 5.5 mmol/L for 30 minutes (baseline plateau). Subsequently, by discontinuation of glucose infusion, plasma glucose was allowed to further decline to 3.5 mmol/L, a level that was again kept for 30 minutes. Thereafter, the procedure was repeated to reach and maintain a second hypoglycaemic plateau at 2.5 mmol/L for 30 minutes. After 15 minutes of the second hypoglycaemic plateau, insulin infusion was terminated and glucose infusion was tapered off to allow a spontaneous recovery from hypoglycaemia, aiming to achieve plasma glucose of 5.5 mmol/L.
Samples for platelet activation and coagulation markers as well as
values for markers of endothelial function, inflammation and counterregulatory hormones were obtained 30 minutes after reaching the designated plateau as well as after recovery from hypoglycaemia at a plasma glucose level of 5.5 mmol/L.
To ensure safety, participants were monitored with an ECG throughout both clamp experiments.
| Follow-up visits
Participants were instructed to return to the study centre 1 and 7 days after the hypoglycaemic clamp experiment in order to have blood drawn to assess platelet activity, coagulation, endothelial function and inflammatory markers as well as counterregulatory hormones to evaluate delayed or sustainable effects of the hypoglycaemic event.
2.6 | Analytical methods The concentration of soluble semaphorin 4D (Sema4D) in freshly thawed EDTA plasma aliquots was quantified using a commercially available kit ELISA (Biomedica, Vienna, Austria) as recommended by the manufacturer. The intra-and interassay coefficients of variation were given as ≤8% and ≤ 11%, respectively. Further analytical methods are described in the Supporting Information.
| Platelet activity measures
| Statistical analyses
The statistical analyses were performed with SAS software version 9.4 (SAS Institute, Cary, North Carolina). Demographic and baseline characteristics were summarized and tabulated as means ± SD or median and minimum and maximum for quantitative variables and frequencies and percentages for categorical variables. 
| Sample size calculation
We have shown previously that LTA based on ADP activation in a population with type 2 diabetes is 70 ± 12%. 26 For a clinically relevant difference in LTA from baseline to hypoglycaemia of 10% and assuming a standard deviation of the differences of 12%, 14 participants were needed to achieve a power of 80% using a paired t test with a .05 two-sided significance level. One participant who dropped out was replaced in order to retain adequate power. 
| RESULTS
In total, 19 volunteers were screened for the study, of whom four did not qualify for enrolment (one with steroid replacement therapy, three
with HbA1c values outside the inclusion range). One participant was excluded from the trial after the second clamp procedure when we became aware that he was not fulfilling all inclusion criteria (participant was using insulin intermittently). This participant was also excluded from the final analysis. Finally, 14 participants (10 men and four women, age 55 ± 7 years, BMI 28.9 ± 3.3 kg/m 2 ) were included in the statistical analysis. Detailed baseline characteristics and demographic data are summarized in Table 1 . All clamp experiments were conducted without any related adverse events.
| Blood glucose and counterregulatory hormones
The baseline glucose values prior to the initiation of the clamp experiments were 7.2 ± 1.2 mmol/L (hypoglycaemic clamp) and 7.1 ± 1.0 mmol/L (euglycaemic clamp). Detailed glucose levels achieved during the hyperinsulinaemic-hypoglycaemic clamp experiments are shown in Table S1 . Figure S1 ).
| Platelet activation markers
Platelet activation markers remained unchanged during the euglycaemic clamp experiment ( Figure S2 ). Figure 2F ).
Changes in platelet activation
| Markers of coagulation
During the euglycaemic clamp coagulation markers remained stable (D-dimer, von Willebrand factor activity, factor VIII) or numerically Figure S4A -C]).
| Markers of endothelial function and inflammation
Levels of VCAM and ICAM did not change during the hypoglycaemic clamp experiment, but increased thereafter, reaching a peak at day 7, the increase for VCAM reaching statistical significance (P < .01). IL-6 acutely and significantly increased during the hypoglycaemic clamp and reached a peak at the end of the clamp (P < .001 compared to baseline). This increase was not sustained and no increases were observed 24 hours or 7 days after hypoglycaemia ( Figure 4A-C) . IIb/IIIa complex on the platelet surface, while they do not if the complex is quiescent. 27 In the present study we were able to show activa- In contrast to platelet activation, the markers of the coagulation system showed a consistent activation response to hypoglycaemia. It is striking that this activation was not observed during the hypoglycaemic event itself, but consistently 1 day after the clamp procedure. This activation seems to be sustained for most of the variables assessed for 1 week after the hypoglycaemic episode.
vWF activity is a surrogate marker for endothelial function inducing platelet-monocyte aggregation, and during the present study we noticed a significant increase in this marker following hypoglycaemia.
These results are in line with data shown previously which demonstrated similar vWF properties in people with type 1 diabetes but not in healthy individuals. 16 Zakai et al 30 recently suggested elevated factor VIII levels to be predictive of coronary heart disease and stroke, and this risk was more pronounced in patients with known diabetes. In the present experiment, factor VIII was significantly increased after hypoglycaemia and remained elevated for 1 week.
PAI-1, a platelet-derived protein, represents an important key component of the haemostatic system, inhibiting the cleavage of plasminogen to plasmin and hence inhibiting fibrinolysis. In the present study, PAI-1 concentrations were significantly increased 24 hours after hypoglycaemia and remained elevated over the following 6 days, suggesting reduced fibrinolytic activity after a prior hypoglycaemic episode. Data from the Framingham Heart Study identified increased PAI-1 as a strong predictive marker for cardiovascular events even after adjusting for established risk factors. 31 Our finding again corresponds with the results reported by Chow et al 28 showing delayed clot lysis after hypoglycaemia. Interestingly, we observed a drop in PAI-1 in all clamps shortly after the initiation of the insulin infusion, a finding that was reported previously, suggesting a direct insulin mediated PAI-1-lowering effect. 21, 28 Soluble Sema4D, also known as Cluster of Differentiation 100 (CD100), represents an integral membrane surface protein expressed mainly by T cells where it supports B cell development 32 ;
its main function comprises the support of intracellular signal transduction and axon guidance in the central nervous system. 33 However, Sema4D has also been shown to be expressed by platelets and, at this stage, it might be involved in repairing of vascular injury by inducing angiogenic responses from endothelial cells and interfering with monocyte migration. 34 Sema4D was identified to act as a potential biomarker for acute heart failure, 35 and a loss of expression was described to reduce platelet hyperactivity and consequently might prevent the development of atherosclerosis and cardiovascular disease. 36 However, Sema4D levels during hypoglycaemia in people with type 2 diabetes have not yet been investigated. The present study provides the first evidence that an acute hypoglycaemic event leads to an increase in Sema4D levels, an effect which was most pronounced 7 days after hypoglycaemia. The role of Sema4D in atherothrombosis in people with diabetes mellitus will need to be further explored.
The present study has some limitations, including the fact that 14 people with diabetes could be considered a small patient group;
however, this study, together with other small mechanistic studies performed in patients with type 2 diabetes, 28, 29 provides evidence of platelet and coagulation activation after a single hypoglycaemic event.
Given the unpleasant side effects involved in participating in a hypoglycaemic clamp procedure, sample sizes need to be kept at a minimum for this type of mechanistic study. Furthermore, we used light aggregometry as the primary outcome measure, based on which we powered the analysis. However, we believe that flow cytometrybased platelet activation assays are more sensitive to moderate changes observed during hypoglycaemia.
In addition, given the delayed activation of platelet and coagulation markers in the present study, we still cannot determine at which glycaemic threshold this activation occurs. To build on the knowledge obtained from the present study and the recent publication by Chow et al, 28 further studies are needed with separate hypoglycaemic clamps using different hypoglycaemic targets to identify the threshold at which platelet and coagulation activation occurs.
Given that the activation in platelet and coagulation markers was delayed, we were not able to rule out activation occurring after the euglycaemic clamp as a result of the insulin infusion as well. Hence, after the data were available, we invited the participants again for another euglycaemic clamp, with subsequent follow-up 1 day and 1 week thereafter ( Figure S5 ). Six participants were willing to participate. While we did not observe a statistically significant platelet or coagulation activation 1 or 7 days after the euglycaemic clamp procedure, a numerical increase in some of the markers from the end of the clamp to day 1 was evident ( Figures S6 and S7) . In contrast to the hypoglycaemic clamp where platelet activation was sustained or even further increased over the following 6 days, all platelet activation markers returned even numerically to baseline levels 1 week after the euglycaemic clamp. Hence, given the sample size of six people in the additional euglycaemic clamp experiment we can not entirely rule out an insulin infusion-induced short-term activation of platelets 1 day after the clamp, as has been shown previously in other settings. 37 However, clearly the activation observed after the hypoglcaemia is more pronounced and sustainable for >1 week after the hypoglycaemic event. Based on the present study we cannot fully explain the mechanisms by which the platelet and coagulation activation after hypoglcaemia occurs, but considering the lifespan of platelets being 7 to 10 days, the observed sustained activation even 1 week after hypoglcaemia seems to be triggered by a subsequent mechanism following the blood glucose drop (eg, stress hormone release), which lasts longer than the low glucose level itself.
The main strength of the present study lies in its design, which included the stepwise hypoglycaemic clamp, and its homogenous patient group who were all on metformin only, with no participant taking antiplatelet drugs or other agents known to affect platelet activity at any time during the trial.
This study provides evidence for the activation of platelet reactivity and coagulation after hypoglycaemia. The observed effect seems to be sustained for 1 week after the event. Our data support the hypothesis that hypoglycaemic events could be one reason for the detrimental effects observed with intensive glucose-lowering using drugs with high hypoglycaemic potency such as in the ACCORD trial. 7, 8 Future trials investigating intensive glucose-lowering using novel drugs with no or very low risk of hypoglycaemia are needed to clarify the open question of the best glycaemic treatment target in people with type 2 diabetes.
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